biotech · Huntington Disease · Alzheimer Disease · VYGR
Voyager Therapeutics
Voyager Therapeutics is a biotech organization headquartered in Lexington, USA. It trades on NYSE under ticker VYGR. Primary therapeutic focus areas include Huntington Disease, Alzheimer Disease, Alzheimer's Disease, Alz
Lexington, USA HQ
2014 Founded
168 Employees
Public company Type
VYGR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Lexington, USA
- Founded
- 2014
- Employees
- 168
- Programs
- 4
- Drugs
- 4
- Patents
- 31
Intraparenchymal rAAV1 - (mi)RNA HTT
Phase 1 · gene therapy · Huntington Disease
Intraparenchymal rAAV1 - (mi)RNA HTT for Huntington Disease is a Phase 1 program (gene_therapy) at Voyager Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code VY-HTT01-1
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Voyager Therapeutics
- Phase
- Phase 1
- Modality
- gene_therapy
- Indication
- Huntington Disease
- Status
- terminated
- Trials
- 1